Related references
Note: Only part of the references are listed.Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor Positive Early Breast Cancer
Shin Hye Yoo et al.
CLINICAL BREAST CANCER (2020)
The Correlation of Magee Equations™ and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
Atilla Soran et al.
EUROPEAN JOURNAL OF BREAST HEALTH (2020)
Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
Hee Jun Choi et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
Amila Orucevic et al.
BREAST (2019)
Oncotype DXA® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy
Alison M. Pease et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Characterizing Response to Neoadjuvant Chemotherapy in Invasive Lobular Breast Carcinoma
Luis A. Riba et al.
JOURNAL OF SURGICAL RESEARCH (2019)
A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor-Positive, Human Epidermal Growth Factor 2 (HER2)-Negative Breast Cancer
Sae Byul Lee et al.
CANCER RESEARCH AND TREATMENT (2019)
A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer
Olga Kantor et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Application of ACOSOG Z1071: Effect of Results on Patient Care and Surgical Decision-Making
Jacquelyn A. Palmer et al.
CLINICAL BREAST CANCER (2018)
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era
Eleftherios P. Mamounas et al.
NPJ BREAST CANCER (2018)
Molecular Genomic Testing for Breast Cancer: Utility for Surgeons
Oluwadamilola M. Fayanju et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Amila Orucevic et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
Paul Baron et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
A Model to Predict Pathologic Complete Response of Axillary Lymph Nodes to Neoadjuvant Chemo(Immuno)Therapy in Patients With Clinically Node-Positive Breast Cancer
Robert-Jan Schipper et al.
CLINICAL BREAST CANCER (2014)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Commentary on The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay
J. Dirk Iglehart et al.
AMERICAN JOURNAL OF SURGERY (2012)
Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas:: a retrospective study on 860 patients from one institution
M. Tubiana-Hulin et al.
ANNALS OF ONCOLOGY (2006)
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial
RE Mansel et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma
VF Cocquyt et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Share Paper
